Afamelanotide mastery course
Unit 9 of 12
Safety and monitoring
Afamelanotide has a well-characterized safety profile from its trials and registries, which this unit separates from th…
What the clinical safety record actually shows
Afamelanotide has a well-characterized safety profile from its trials and registries, which this unit separates from the noisier gray-market reports. The common effects are mild, and the most-feared risk, melanoma, has no clinical signal in the EPP cohorts.
It also draws the firm line the dossier insists on: Melanotan II harms must not be extrapolated to afamelanotide. The molecules, formulations, and monitoring contexts differ fundamentally.